Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:CTMXNASDAQ:CUENASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.54+0.6%$1.54$1.11▼$17.88$21.91M1.46719,160 shs180,007 shsCTMXCytomX Therapeutics$2.13+129.4%$0.69$0.40▼$2.18$74.85M1.111.95 million shs113.23 million shsCUECue Biopharma$0.75-3.7%$0.84$0.45▼$1.99$46.43M1.51429,201 shs159,546 shsPRPHProPhase Labs$0.33+7.9%$0.35$0.22▼$5.45$13.69M-0.472.67 million shs587,952 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%-4.95%+17.53%-43.44%-74.11%CTMXCytomX Therapeutics0.00%+15.76%+74.35%+17.49%-53.11%CUECue Biopharma0.00%+3.64%+1.81%-41.35%-55.17%PRPHProPhase Labs0.00%-8.38%-1.78%+15.43%-94.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.1173 of 5 stars3.54.00.00.00.01.70.6CTMXCytomX Therapeutics4.252 of 5 stars3.31.00.04.73.22.51.3CUECue Biopharma4.105 of 5 stars3.52.00.04.72.50.81.3PRPHProPhase Labs1.1016 of 5 stars0.02.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$40.672,542.41% UpsideCTMXCytomX Therapeutics 2.67Moderate Buy$4.2599.53% UpsideCUECue Biopharma 3.00Buy$3.00299.47% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CTMX, CUE, PRPH, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.503/7/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/7/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/ACTMXCytomX Therapeutics$138.10M1.24N/AN/A($0.71) per share-3.00CUECue Biopharma$9.29M5.00N/AN/A$0.82 per share0.92PRPHProPhase Labs$6.77M2.02N/AN/A$2.74 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$2.56N/AN/AN/AN/AN/A-311.00%5/12/2025 (Estimated)CTMXCytomX Therapeutics-$570K$0.3812.53N/AN/A10.96%-41.47%8.11%5/12/2025 (Estimated)CUECue Biopharma-$50.73M-$0.75N/AN/AN/A-468.02%-156.38%-88.07%N/APRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%N/ALatest CTMX, CUE, PRPH, and ANVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ANVSAnnovis Bio-$0.47N/AN/AN/AN/AN/A5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million5/8/2025Q1 2025CUECue Biopharma-$0.15-$0.17-$0.02-$0.17$0.90 millionN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/A3/6/2025Q4 2024CTMXCytomX Therapeutics-$0.23$0.22+$0.45$0.22$13.53 million$38.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.662.66CTMXCytomX TherapeuticsN/A1.041.04CUECue Biopharma0.052.222.22PRPHProPhase Labs0.481.471.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CTMXCytomX Therapeutics67.77%CUECue Biopharma35.04%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio32.30%CTMXCytomX Therapeutics7.00%CUECue Biopharma10.78%PRPHProPhase Labs20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio314.24 million9.64 millionOptionableCTMXCytomX Therapeutics17080.62 million72.78 millionOptionableCUECue Biopharma6061.82 million55.58 millionOptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableCTMX, CUE, PRPH, and ANVS HeadlinesRecent News About These CompaniesProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024March 31, 2025 | globenewswire.comProPhase Labs FY 2024 Earnings PreviewMarch 28, 2025 | msn.com6PRPH : An Overview of ProPhase Labs's EarningsMarch 28, 2025 | benzinga.comProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025March 27, 2025 | globenewswire.comProPhase Labs, Inc. CEO Ted Karkus to Present at Q1 Investor Summit Virtual on March 11thMarch 7, 2025 | quiverquant.comProPhase Labs to Present at the Investor Summit Virtual on March 11March 7, 2025 | globenewswire.comBears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' NowMarch 5, 2025 | zacks.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 26, 2025 | globenewswire.comProPhase Labs examines opportunities to leverage DTC multi-media infrastructureFebruary 25, 2025 | markets.businessinsider.comProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription DrugsFebruary 25, 2025 | globenewswire.comProPhase Labs provides update on cash generation initiativesFebruary 20, 2025 | markets.businessinsider.comProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 ReceivablesFebruary 20, 2025 | globenewswire.comProPhase Labs hires Stuart Hollenshead as COOFebruary 19, 2025 | markets.businessinsider.comProPhase Labs hires former Barstool Sports COO Stuart Hollenshead, plans cost-cutting measuresFebruary 19, 2025 | msn.comProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool SportsFebruary 18, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Stock: More Strategic Than Meets the EyeFebruary 4, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTMX, CUE, PRPH, and ANVS Company DescriptionsAnnovis Bio NYSE:ANVS$1.54 +0.01 (+0.59%) Closing price 03:58 PM EasternExtended Trading$1.55 +0.01 (+0.71%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.CytomX Therapeutics NASDAQ:CTMX$2.13 +1.20 (+129.43%) Closing price 04:00 PM EasternExtended Trading$1.99 -0.14 (-6.57%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Cue Biopharma NASDAQ:CUE$0.75 -0.03 (-3.68%) Closing price 04:00 PM EasternExtended Trading$0.74 -0.01 (-0.80%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.ProPhase Labs NASDAQ:PRPH$0.33 +0.02 (+7.92%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.61%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
